Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Daiichi Sankyo

Status and phase

Completed

Phase 2

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: placebo

Drug: Colesevelam hydrochloride

Study type

Interventional

Funder types

Industry

Identifiers

NCT00361153

WEL-202

Details and patient eligibility

About

This study is designed to test whether WelChol (colesevelam HC1) improves blood sugar control in patients with type 2 diabetes by making their own insulin work more efficiently.

Full description

Single-center, randomized, parallel, double-blind, placebo controlled, 8-week trial in subjects with type 2 diabetes mellitus. Two parallel treatment groups include double-blind colesevelam or placebo. A screening period may be up to 18 weeks to withdraw non sulfonylurea antidiabetic treatment or withdraw or adjust sulfonylurea antidiabetic treatment. To evaluate hepatic and peripheral insulin sensitivity, subjects will undergo a two-step hyperinsulinemic-euglycemic clamp with a tritiated glucose infusion at pre randomization and after 8 weeks of treatment. To evaluate oral glucose absorption, subjects will undergo two oral glucose tolerance tests (OGTT) at pre randomization, one without colesevelam and one with colesevelam, and one OGTT at the end of the treatment period..

Enrollment

35 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the trial:

Have given written informed consent
Ages 18 to 75 years, inclusive
Diagnosis of type 2 diabetes mellitus of at least 3 months duration
HbA1C 7.0- 10.0%, inclusive
Antidiabetic treatment may include oral agents; all antidiabetic agents must be withdrawn before randomization
Women may be enrolled if they are not pregnant (negative serum βHCG at the Screening Visit), are not breast-feeding, and do not plan to become pregnant during the trial. In addition, they must either have had a hysterectomy or tubal ligation at least 6 months before signing informed consent, be post-menopausal for 1 year, or practicing an acceptable method of birth control. An acceptable method of birth control may be oral, injectable or implantable hormonal contraceptives, intrauterine device, diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy are NOT acceptable methods of contraception
BMI 25 - 45 kg/M sq, inclusive

Exclusion criteria

Subjects are excluded from participation in the study if any of the following criteria apply:

Type 1 diabetes mellitus or history of diabetic ketoacidosis
Treatment with lipid or blood pressure lowering therapy that has not been stable for three months before randomization
Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the last 3 months
Treatment with thiazolidinediones
History of dysphagia, swallowing disorders, or intestinal motility disorder
Serum triglyceride >500 mg/dL at Visit 1
Serum LDL-C <60 mg/dL at Visit 1
Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject or makes participation not in the subject's best interest
Use of any investigational drug within 30 days before randomization
Chronic treatment with oral corticosteroids
History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine